Starling Oncology, Inc.

Starling Oncology, Inc.

NNASDAQ:STLN
3.54
USD
+0.04
(+1.14%)
-0.35EPS
644.58MMarket Cap
Mar 11Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
2.41
2.91
3.07
3.47
4.4
5.24
5.44
6.04
Basic EPS, GAAP
- -
-0.06
-0.22
-0.16
- -
-1.13
-0.86
-0.66
-0.35
Free Cash Flow per Basic Share
- -
0.04
-0.01
-0.54
-0.92
-0.55
-0.4
-0.3
0.18
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.08
-0.7
1.42
1.68
0.77
0.05
-0.16
-0.37
Tangible Book Value per Share
- -
-0.56
-1.15
0.81
1.14
0.43
-0.24
-0.34
-0.52
Basic Weighted Avg Shares
- -
64
64
66
73
74
75
92
103
Sales/Revenue/Turnover
113
155
188
203
252
324
393
503
620
Operating Margin (%)
4.23
-1.7
-4.37
-22.59
-28.52
-18.55
-15.28
-7.18
-3.39
Depreciation Expense
1
3
3
3
4
6
6
7
7
Net Income, GAAP
4
-4
-14
-11
- -
-83
-65
-61
-36
Effective Tax Rate (%)
18.78
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
3.49
-2.59
-7.64
-5.38
0.06
-25.62
-16.44
-12.06
-5.73
Working Capital
- -
8
1
124
101
109
60
42
14
LT Debt
- -
- -
7
- -
103
113
116
97
90
Total Equity
- -
42
28
104
123
57
4
-16
-37
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
0.13
-92.2
-213.36
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
7
7
12
LT Borrowings
79
80
73
LT Finance Leases
19
17
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
100
102
Market Capitalization
- -
- -
645

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
117
129
138
Cash, Cash Equivalents & STI
30
41
37
Accounts Receivable, Net
58
66
61
Inventories
24
20
37
Total Current Liabilities
79
95
124
Payables & Accruals
57
73
95
ST Debt
7
7
12
Deferred Revenue
2
2
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-79.3%
-538.01%
Free Cash Flow
- -
1,024.58%
-8.38%
Net Income, GAAP
- -
-10,980.7%
-6.27%
Sales/Revenue/Turnover
- -
22.03%
27.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
95
99
100
100
393
2025
104
120
137
142
503
2026
147
161
170
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.27
-0.21
-0.21
-0.17
-0.86
2025
-0.25
-0.18
-0.17
-0.07
-0.66
2026
-0.02
-0.1
-0.15
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Daniel Virnich
Full Time Employees
641
Sector
Health services
Industry
Medical/Nursing services
Address
18000 Studebaker Road, Suite 800 Cerritos CA United States 90703
IPO Date
Mar 13, 2020
Business
Starling Oncology, Inc. engages in the development and commercialization of targeted cancer therapies and related oncology solutions. The company designs, manufactures, licenses, and distributes pharmaceutical products and biologics focused on oncologic indications, including monoclonal antibodies, antibody-drug conjugates, small molecule inhibitors, and companion diagnostic tools. It provides oncology therapeutics across multiple lines, including late-stage clinical programs and approved treatments, with a portfolio spanning solid tumor and hematologic malignancy indications. The firm develops, sources, manufactures, and commercializes its products through collaborations and direct distribution channels. Main products and services: core oncology therapeutics and diagnostic solutions; research and development services in oncology, including preclinical and clinical development support; manufacturing and process development for biologics and small molecules; regulatory affairs and pharmacovigilance; commercialization activities including product launches, market access, and physician education; companion diagnostics and precision medicine services; strategic partnerships and licensing agreements; contract development and manufacturing organization (CDMO) services for third-party customers; portfolio management and life-cycle management of oncology assets. Latest major company changes: forms strategic partnerships and alliances with pharmaceutical and biotechnology collaborators to advance pipeline programs; completes funding rounds and secures additional capital to support clinical development and manufacturing scale-up; advances or completes acquisitions or asset purchases related to oncology portfolios; launches new product candidates or expands indications for existing therapies; undergoes corporate reorganizations or branding updates to reflect strategic focus; initiates significant operational scaling, including manufacturing capability expansions and geographic market entries within the last 1–2 years. Additional context: industry and business segments include oncology therapeutics, diagnostics, and life sciences services; targets hospitals, specialty clinics, and research institutions with oncology patient populations; geographic operations span North America, Europe, Asia-Pacific, and other international markets; founded in [year], headquartered in [location], with potential subsidiaries and parent relationships as part of a broader corporate group; maintains collaboration networks, including licensees, contract manufacturers, and research partners.

Company News

  • Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcript

  • Oncology Institute Q3 Earnings Call Highlights

  • Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates

  • Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

  • Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call

  • Oncology Institute (NASDAQ:STLN) Shares Climb 6.1% – Should You Buy?

  • Cedar Grove Capital Q3 2026 Portfolio Update

  • Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation

  • Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating

  • Starling Oncology to Participate in Wells Fargo Healthcare Conference

  • Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

  • Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

  • The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates